Share chart Genprex, Inc.
Extended chart
Simple chart
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
EBITDA |
-0.0106 |
Число акций ао |
0.0013677 млрд |
P/BV |
1.49 |
EV/EBITDA |
-0.2352 |
Цена ао |
2.74 |
ISIN |
US3724461047 |
Сайт |
https://www.genprex.com
|
Валюта |
usd |
IPO date |
2018-03-29 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Change price per day: |
+3.03% (0.33) |
Change price per week: |
-8.36% (0.371) |
Change price per month: |
-31.86% (0.499) |
Change price per 3 month: |
-81.72% (1.86) |
Change price per half year: |
-88.93% (3.07) |
Change price per year: |
-3.41% (0.352) |
Change price per 3 year: |
-87.81% (2.79) |
Change price per 5 year: |
-61.36% (0.88) |
Change price per year to date: |
+38.78% (0.245) |
|
Underestimation
Title |
Value |
Grade |
P/S |
0 |
0 |
P/BV |
1.56 |
8 |
P/E |
0 |
0 |
EV/EBITDA |
-0.1567 |
0 |
Total: |
|
3.5 |
|
Efficiency
Title |
Value |
Grade |
ROA, % |
-289.21 |
0 |
ROE, % |
-416.11 |
0 |
Total: |
|
0 |
|
|
Dividends
Title |
Value |
Grade |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0 |
|
Debt
Title |
Value |
Grade |
Debt/EBITDA |
0 |
10 |
Total: |
|
10 |
|
Growth impulse
Title |
Value |
Grade |
Yield Revenue, % |
0 |
0 |
Yield Ebitda, % |
193.02 |
10 |
Yield EPS, % |
3302.65 |
10 |
Total: |
|
8 |
|
Head |
Job title |
Payment |
Year of birth |
Mr. David M. Schloss |
Senior Vice President of Human Resources |
N/A |
|
Mr. Thomas C. Gallagher Esq. |
Senior Vice President of Intellectual Property & Licensing |
N/A |
|
Dr. Mark S. Berger M.D. |
Chief Medical Officer |
528.16k |
1955 (69 years) |
Mr. Ryan M. Confer M.S. |
President, CEO, CFO & Director |
|
1982 (42 years) |
Dr. Suzanne Thornton-Jones Ph.D. |
Senior Vice President of Regulatory Affairs & Quality |
|
|
Dr. Jack A. Roth F.A.C.S., M.D. |
Chairman of Scientific & Medical Advisory Board |
|
|